Medicana Health Group’s Prof. Suat Büket, MD explains how selected bypass and heart-valve procedures can be completed without dividing the breastbone while maintaining the same surgical objective Photo: Robotic heart surgery at Medicana Health Group via FL Comms ISTANBUL, Sept. 09, 2026 (GLOBE NEWSWIRE) — For selected heart patients, complex surgery can now be performed through several small openings between the ribs rather than by dividing the breastbone. Robot-assisted cardiac surgery combines a surgeon-controlled console with high-definition three-dimensional imaging, tremor filtration and highly articulated instruments, offering a minimally invasive route to procedures that have traditionally required a full sternotomy. Prof. Suat Büket, MD, a cardiovascular surgeon at Medicana Health Group, said the most important point is often misunderstood: the robot does not perform the operation independently. “The surgeon remains in control at every stage. The system translates the surgeon’s hand movements into precise movements inside the chest. Its value lies in giving us a magnified three-dimensional view and a range of motion that is difficult to achieve with conventional instruments through a small opening,” said Prof. Büket. Photo: Prof. Suat Büket, MD via FL Comms Several small ports instead of a divided breastbone In conventional open-heart surgery, access to the heart often requires a midline incision and division of the sternum. The bone is then rejoined at the end of the operation and must heal over the following weeks, during which patients may face movement restrictions. Wound and bone-healing complications can be particularly challenging for patients with certain risk factors. In robot-assisted cardiac surgery, the surgical team can access the chest through three or four ports between the ribs, each approximately one centimetre, depending on the planned operation. A camera and the robotic instruments are introduced through these openings. The surgeon operates from a console in the operating theatre while the bedside team supports the procedure. Technology expands the surgeon’s view and reach The system’s high-definition camera provides a three-dimensional, magnified view of the operative field. Wristed instruments can bend and rotate beyond the range of the human hand, while computer-assisted tremor filtration supports steady movement. These features are designed to help the surgeon work precisely in confined anatomical spaces; they do not replace clinical judgement or the surgical team. The robot is a surgical instrument — not an autonomous decision-maker. Patient selection, operative planning and every surgical movement remain the responsibility of the trained clinical team. The surgical objective does not change Prof. Büket stressed that a minimally invasive approach should not mean a reduced operation. When robot-assisted surgery is clinically appropriate, the aim is to complete the same planned cardiac repair or revascularisation that would otherwise be performed through an open approach. “If the plan is to perform bypass grafting or repair or replace a heart valve, the objective remains the same. The difference is the route we use to reach the heart. A smaller incision must never mean an incomplete procedure,” he said. Recovery benefits depend on the right patient Avoiding sternotomy may reduce the burden of bone healing and allow some patients to return to everyday movement sooner. Smaller incisions may also reduce wound-related concerns and can offer cosmetic and psychosocial benefits. However, not every patient is a candidate. The decision depends on the planned procedure, anatomy, previous operations, vascular access and the findings of pre-operative tests. “Robotic cardiac surgery is not automatically the best option simply because the incisions are smaller,” Prof. Büket said. “The safest and most effective approach is selected after a complete assessment. Technology adds value when it is matched to the right patient, the right procedure and an experienced team.” From precision tools to connected operating rooms Robot-assisted surgery also points toward a more connected future for operating theatres. Research into remote surgical support and telesurgery continues, but current practice still depends on a trained surgical team, specialist infrastructure and direct clinical oversight. For Prof. Büket, the immediate priority is not distance but precision: using the technology available today to reduce surgical trauma without compromising the completeness or safety of the operation. About Medicana Health Group Founded in 1992, Medicana Health Group is one of Türkiye’s leading privately owned healthcare providers, operating 19 hospitals in Türkiye, the United Kingdom, and Bosnia and Herzegovina. Serving more than 5 million patients annually, including a significant international patient base, Medicana delivers multidisciplinary care across a broad range of specialties with a strong focus on clinical excellence and patient-centered service. In addition to healthcare, the Group invests in education through Medicana Education Group and Fenerbahçe University. With approximately 15,000 employees, Medicana continues to expand its international footprint while advancing sustainability through renewable energy investments and supporting Turkish sports through long-term health sponsorships. Media contact Uğur AlkaparGlobal Media Relations DirectorFL Communicationsugur@flcommunications.co.uk This press release is intended for general informational purposes. Treatment decisions must be made by qualified clinicians following an individual patient assessment. Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7b10f86c-bc1f-41a5-a99e-3a5afb79b174 https://www.globenewswire.com/NewsRoom/AttachmentNg/92e8455e-008d-4a4a-9c60-1b85de881324
Tag: cardiovascular
FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with type 2 diabetes at high risk for these events – in addition to its established A1C and weight loss benefits It is estimated that as many as one in…
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
In ACHIEVE-4, Foundayo met the primary objective of non-inferiority vs. insulin glargine with a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events In a pre-planned analysis, the risk of all-cause death was 57% lower for Foundayo vs. insulin glargine, showing the…
GE HealthCare unveils Vivid Pioneer, its most advanced AI-powered cardiovascular ultrasound system, designed to enhance speed and image quality for improved diagnostic confidence and workflow efficiency
CHICAGO–(BUSINESS WIRE)–GE HealthCare (Nasdaq: GEHC) today announced the launch of the Vivid™ Pioneer, its most advanced, ultra-premium and adaptive cardiovascular ultrasound system yet, completely redesigned to support clinicians with extraordinary imaging in 2D, 4D and color flow, streamlined workflow, and enhanced diagnostic confidence. The ultrasound system recently received CE Mark […]
Octane’s 4th Annual Cardiovascular Tech Forum to Feature More Than 50 Experts Who Share Latest Developments and Innovations in Cardiovascular Healthcare Sept. 11-12
Two-Day Forum Offers an Opportunity to Network with Industry Leaders Exploring the Future of Cardiovascular Technology, Reviewing Its Breakthroughs, Evaluating the Advanced Solutions Shaping the Sector, and Appraising Investment Opportunities NEWPORT BEACH, Calif., July 14, 2025…
Study Shows High Volume Exercise Unrelated to Progression of Coronary Artery Calcium
New research from The Cooper Institute® + partners shows exercising, even at very high levels, is unrelated to progression of coronary artery calcium (CAC)
ConcertAI’s TeraRecon Adds Cardio Suite to its Eureka Clinical AI Platform
CAMBRIDGE, Mass., Aug. 30, 2023 /PRNewswire/ — Concert AI’s TeraRecon, the advanced visualization and clinical AI SaaS company, announced today that its Eureka Clinical AI platform’s Cardio Suite now provides clinicians with the state-of-the-art artificial intelligence and deep learning technology necessary to help identify, treat, and manage cardiovascular disease. Eureka Clinical AI […]
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
EAST HANOVER, N.J., Aug. 28, 2023 /PRNewswire/ — Novartis today announced new long-term data from ORION-8, a Phase III open-label extension of ORION-9, ORION-10, ORION-11 and ORION-3 trials. The data demonstrated that with twice-yearly* dosing, Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six years in patients […]
FDA Clears Numares Health Cardiovascular Diagnostic Test and Core Technology Platform
THE WOODLANDS, Texas and REGENSBURG, Germany, July 25, 2023 /PRNewswire/ — The US Food and Drug Administration has cleared a Numares Health test, the AXINON® LDL-p Test System, as a new tool physicians can use to measure lipoproteins for patients at risk for cardiovascular disease. Currently, Numares is the only company in the US selling an FDA-cleared […]
Nationwide Preventive Healthcare Company, Life Line Screening, Announces Ray Li as Vice President of Product
AUSTIN, Texas–(BUSINESS WIRE)–Life Line Screening, the nation’s leading mobile preventive health screening company for cardiovascular disease and stroke risk, announces that Ray Li has joined the organization as Vice President of Product. Mr. Li joins Life Line Screening as the business is focused on providing the highest level of preventive […]


